Taysha Gene Therapies (NASDAQ:TSHA) Rating Increased to Strong-Buy at Truist Financial

Truist Financial upgraded shares of Taysha Gene Therapies (NASDAQ:TSHA) to a strong-buy rating in a report released on Wednesday morning,Zacks.com reports.

A number of other analysts have also recently issued reports on TSHA. Needham & Company LLC raised their price objective on Taysha Gene Therapies from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Thursday, March 19th. Chardan Capital reissued a “buy” rating and set a $12.00 target price on shares of Taysha Gene Therapies in a report on Thursday, March 19th. UBS Group set a $11.00 price target on Taysha Gene Therapies in a research note on Thursday, December 4th. The Goldman Sachs Group set a $11.00 price target on Taysha Gene Therapies in a report on Thursday, December 4th. Finally, Wall Street Zen raised shares of Taysha Gene Therapies from a “sell” rating to a “hold” rating in a research report on Saturday, March 21st. Two investment analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Taysha Gene Therapies currently has a consensus rating of “Buy” and a consensus target price of $11.09.

Taysha Gene Therapies Stock Up 10.9%

Shares of TSHA stock opened at $4.58 on Wednesday. The company has a debt-to-equity ratio of 0.20, a quick ratio of 12.23 and a current ratio of 12.23. The firm’s 50-day moving average is $4.60 and its 200-day moving average is $4.58. The stock has a market cap of $1.32 billion, a price-to-earnings ratio of -13.47 and a beta of 1.02. Taysha Gene Therapies has a 52-week low of $1.05 and a 52-week high of $6.02.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its earnings results on Thursday, March 19th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.03. Taysha Gene Therapies had a negative net margin of 1,144.97% and a negative return on equity of 56.64%. The business had revenue of $5.49 million during the quarter, compared to the consensus estimate of $1.89 million. Sell-side analysts predict that Taysha Gene Therapies will post -0.35 EPS for the current year.

Insider Transactions at Taysha Gene Therapies

In other news, insider Sukumar Nagendran sold 26,918 shares of the business’s stock in a transaction that occurred on Monday, January 26th. The stock was sold at an average price of $4.61, for a total transaction of $124,091.98. Following the completion of the sale, the insider owned 1,317,389 shares in the company, valued at $6,073,163.29. The trade was a 2.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Kamran Alam sold 23,849 shares of the company’s stock in a transaction that occurred on Monday, January 26th. The shares were sold at an average price of $4.61, for a total value of $109,943.89. Following the completion of the transaction, the chief financial officer directly owned 1,443,786 shares in the company, valued at $6,655,853.46. The trade was a 1.62% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 598,623 shares of company stock worth $2,822,188 over the last quarter. Company insiders own 3.78% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TSHA. Marex Group plc acquired a new stake in shares of Taysha Gene Therapies during the second quarter worth $29,000. E Fund Management Co. Ltd. bought a new stake in shares of Taysha Gene Therapies in the second quarter valued at about $31,000. ST Germain D J Co. Inc. grew its stake in shares of Taysha Gene Therapies by 81.8% in the third quarter. ST Germain D J Co. Inc. now owns 9,633 shares of the company’s stock valued at $32,000 after acquiring an additional 4,333 shares in the last quarter. Arrowpoint Investment Partners Singapore Pte. Ltd. acquired a new position in shares of Taysha Gene Therapies in the third quarter valued at about $40,000. Finally, Tower Research Capital LLC TRC increased its position in Taysha Gene Therapies by 156.5% during the second quarter. Tower Research Capital LLC TRC now owns 17,606 shares of the company’s stock worth $41,000 after acquiring an additional 10,742 shares during the period. 77.70% of the stock is owned by institutional investors and hedge funds.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.